Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231149 | 0.92 | HRH1 (0.40) | HRH1SLC6A4SLC6A2SLC6A3CARM1 | |
| SCHEMBL22697 | 0.92 | HRH1 (0.40) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL2921788 | 0.90 | HRH1 (0.39) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL676540 | 0.90 | HRH1 (0.39) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22141 | 0.90 | HRH1 (0.39) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL62138 | 0.87 | HRH1 (0.62) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL16987030 | 0.87 | KAT2B (0.37) | HRH1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL26088407 | 0.84 | CARM1 (0.36) | HRH1SLC6A4SLC6A2SLC6A3CARM1 | |
| SCHEMBL4361213 | 0.84 | HRH1 (0.35) | HRH1SLC6A4SLC6A2SLC6A3CHRNB2 | |
| SCHEMBL7020382 | 0.84 | HRH3 (0.53) | SLC6A2SLC6A3CARM1PRMT6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| CN-108699028-B | Substituted 4-phenylpyridines as non-systemic TGR5 agonists | 阿德利克斯公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2020-07-23 | — | — | US | disclosed |
| EP-3672950-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2020-07-01 | — | — | EP | disclosed |
| CN-111148744-A | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019063596-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2019-04-04 | — | — | WO | disclosed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1567505-A2 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004044046-A2 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | ENCYSIVE PHARMACEUTICALS (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | HRH1 1586/4885SLC6A4 3347/4885SLC6A2 3064/4885 |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM3 | HRH1 412/4885SLC6A4 397/4885SLC6A2 626/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | HRH1 1388/4885SLC6A4 3438/4885SLC6A2 2963/4885 |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | VCAM1, ITGB1, ICAM1 | HRH1 1543/4885SLC6A4 3828/4885SLC6A2 3960/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | HRH1 415/4885SLC6A4 332/4885SLC6A2 500/4885 |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | HRH1 1689/4885SLC6A4 2933/4885SLC6A2 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.